African American lung cancer patients may have different response to new cancer-fighting drugs

African American patients with NSCLC are significantly less likely than Caucasian counterparts to harbor activating mutations of the epidermal growth factor receptor (EGFR) gene in their cancers, which suggests that common oral EGFR inhibitor drugs, such as TarcevaŽ (erlotinib), are unlikely to yield dramatic remissions. Additionally, cancer biopsy testing revealed that African American patients with NSCLC are significantly more likely to have increased copies of the EGFR gene than Caucasians. Detection of increased copies of the Her2 gene in breast cancer, a gene closely related to EGFR, has been the basis for major advances in therapy using drugs which target Her2.

"We are finding that ethnicity may play a significant role in a variety of cancers," says Dr. Leidner, an oncologist with Ireland Cancer Center of University Hospitals Case Medical Center and Visiting Instructor at Case Western Reserve University School of Medicine. "It was already known that a higher proportion of East Asian NSCLC patients harbor mutations of the EGFR gene than Caucasians, and that these mutations are associated with a higher likelihood of major responses to EGFR inhibitors. Before our study, however, surprisingly little data existed for African American patients with this common type of lung cancer."

These findings add to a growing body of evidence demonstrating genetic variation in genetic pathways between ethnic groups, and underscores the need for incorporation of these differences into the design of future clinical trials with agents targeting the EGFR pathway.

Epidemiologic studies have suggested that African Americans have a higher risk of NSCLC and have poorer outcomes with treatment. Ethnic background and genetic make-up are linked, and consequently, may impact the likelihood of major responses to oral EGFR inhibiting drugs. For example, in large international lung cancer trials a higher percentage of East Asian NSCLC patients were found to carry drug-sensitizing mutations of the EGFR gene than Caucasians, and as predicted the highest rates of response to EGFR inhibitor drugs were found in the East Asian patients.

The recently published findings have led the researchers to initiate a follow-up study. This multi-center effort will review the overall rates of response, or lack thereof, among African American patients with NSCLC treated at the Case Comprehensive Cancer Center with EGFR inhibitor drugs during the course of their illness.

"In the future, this may lead clinical cancer researchers to be able to take advantage of these findings for a 'smart-design approach' to clinical trials in lung cancer, with novel treatments and biomarkers employed among different patient populations or even individuals," says Stanton Gerson, MD, Director of the University Hospitals Ireland Cancer Center as well as the Case Comprehensive Cancer Center. "Targeted treatments for patients based on a myriad of genetic and ethnic factors are the wave of the future and may lead the way to improved cure rates for our cancer patients."

Source: University Hospitals Case Medical Center